Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

450 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Propofol as a transformative drug in anesthesia: insights from key early investigators.
Bateman BT, Kesselheim AS. Bateman BT, et al. Drug Discov Today. 2015 Aug;20(8):1012-7. doi: 10.1016/j.drudis.2015.04.007. Epub 2015 Apr 30. Drug Discov Today. 2015. PMID: 25936833 Review. No abstract available.
Medical-process patents--monopolizing the delivery of health care.
Kesselheim AS, Mello MM. Kesselheim AS, et al. N Engl J Med. 2006 Nov 9;355(19):2036-41. doi: 10.1056/NEJMhpr063626. N Engl J Med. 2006. PMID: 17093256 No abstract available.
Incentives for drug development--the curious case of colchicine.
Kesselheim AS, Solomon DH. Kesselheim AS, et al. N Engl J Med. 2010 Jun 3;362(22):2045-7. doi: 10.1056/NEJMp1003126. Epub 2010 Apr 14. N Engl J Med. 2010. PMID: 20393164 No abstract available.
Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.
Kesselheim AS, Outterson K. Kesselheim AS, et al. Health Aff (Millwood). 2010 Sep;29(9):1689-96. doi: 10.1377/hlthaff.2009.0439. Health Aff (Millwood). 2010. PMID: 20820028
We review a number of proposals intended to bolster drug development, including such financial incentives for pharmaceutical manufacturers as extending the effective patent life for new antibiotics. ...As an alternative, we recommend a two-prong, "integrated" strate …
We review a number of proposals intended to bolster drug development, including such financial incentives for pharmaceutical manufacturers …
Using market-exclusivity incentives to promote pharmaceutical innovation.
Kesselheim AS. Kesselheim AS. N Engl J Med. 2010 Nov 4;363(19):1855-62. doi: 10.1056/NEJMhle1002961. N Engl J Med. 2010. PMID: 21047231 No abstract available.
Origins of medical innovation: the case of coronary artery stents.
Xu S, Avorn J, Kesselheim AS. Xu S, et al. Circ Cardiovasc Qual Outcomes. 2012 Nov;5(6):743-9. doi: 10.1161/CIRCOUTCOMES.112.967398. Epub 2012 Oct 23. Circ Cardiovasc Qual Outcomes. 2012. PMID: 23093563 Review.
FDA regulation of off-label drug promotion under attack.
Kesselheim AS, Mello MM, Avorn J. Kesselheim AS, et al. JAMA. 2013 Feb 6;309(5):445-6. doi: 10.1001/jama.2012.207972. JAMA. 2013. PMID: 23385267 No abstract available.
450 results
Jump to page
Feedback